Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.
immune checkpoint inhibitor (ICI)
immune microenviroment
regulatory T (Treg) cell
triple negative breast cancer (TNBC)
tumor glycolysis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
10
2022
accepted:
17
11
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into the treatment landscape of TNBC have led to improved outcomes in a subset of patients both in the early stage and metastatic settings. However, a large portion of patients with TNBC remain resistant to immune checkpoint inhibitors and have limited treatment options beyond cytotoxic chemotherapy. The interplay between the anti-tumor immune response and tumor metabolism contributes to immunotherapy response in the preclinical setting, and likely in the clinical setting as well. Specifically, tumor glycolysis and lactate production influence the tumor immune microenvironment through creation of metabolic competition with infiltrating immune cells, which impacts response to immune checkpoint blockade. In this review, we will focus on how glucose metabolism within TNBC tumors influences the response to immune checkpoint blockade and potential ways of harnessing this information to improve clinical outcomes.
Identifiants
pubmed: 36703796
doi: 10.3389/fonc.2022.1061789
pmc: PMC9872136
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1061789Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2023 Schreier, Zappasodi, Serganova, Brown, Demaria and Andreopoulou.
Déclaration de conflit d'intérêts
RZ is an inventor on patent applications related to work on GITR, PD-1, and CTLA-4 (patent numbers: US20180244793A1; US10323091B2; WO2018106864A1; WO2019094352A1). RZ is a scientific advisory board member for iTEOS Belgium SA. SD has received compensation for consultancy/advisory services from Lytix Biopharma, EMD Serono, Ono Pharmaceutical, and Genentech, and research support from Lytix Biopharma and Boehringer-Ingelheim for unrelated projects. AS, IS, KB, and EA do not have any conflicts of interest to declare.
Références
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756919
Trends Pharmacol Sci. 2012 Apr;33(4):207-14
pubmed: 22398146
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
BMC Cancer. 2021 Oct 10;21(1):1093
pubmed: 34629067
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1304-11
pubmed: 23632960
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Drugs Today (Barc). 2003 Mar;39(3):157-74
pubmed: 12730701
Cancer Sci. 2016 Dec;107(12):1730-1735
pubmed: 27727484
Am J Nucl Med Mol Imaging. 2016 Apr 24;6(2):120-7
pubmed: 27186439
Cancer Immunol Res. 2019 Jul;7(7):1064-1078
pubmed: 31088846
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Nucl Med. 2016 Apr;57(4):536-43
pubmed: 26697967
Breast Care (Basel). 2017 Mar;12(1):21-28
pubmed: 28611537
Nature. 2021 Mar;591(7851):652-658
pubmed: 33588426
J Pathol. 2020 Apr;250(5):667-684
pubmed: 32129476
Ceska Gynekol. 2013 Jun;78(3):263-8
pubmed: 23869833
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
Nature. 2021 Mar;591(7851):645-651
pubmed: 33589820
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Nat Rev Endocrinol. 2021 Jun;17(6):350-363
pubmed: 33927368
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Science. 2021 Sep 17;373(6561):1327-1335
pubmed: 34529489
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncogene. 2019 May;38(19):3681-3695
pubmed: 30664688
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
J Clin Invest. 2019 Apr 1;129(4):1785-1800
pubmed: 30753167
Cell Metab. 2021 Jan 5;33(1):51-64.e9
pubmed: 33181091
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
pubmed: 17438091
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Med Chem. 2012 Apr 26;55(8):3827-36
pubmed: 22468970
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
J Nucl Med Technol. 2020 Sep;48(3):278-282
pubmed: 31811061
Cell Metab. 2018 Jul 03;28(1):87-103.e6
pubmed: 29805099
Hum Pathol. 2013 Oct;44(10):2055-63
pubmed: 23701942
Cancer Lett. 2007 Nov 18;257(2):244-51
pubmed: 17910902
Eur J Cancer. 2017 Sep;82:56-65
pubmed: 28648699
Cell Metab. 2018 May 01;27(5):977-987.e4
pubmed: 29628419
Breast Cancer Res. 2016 Mar 15;18(1):33
pubmed: 26975198
Oncotarget. 2017 Sep 12;8(44):77819-77835
pubmed: 29100428
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
PLoS One. 2019 Dec 11;14(12):e0225959
pubmed: 31826010
J Biol Chem. 1995 Jan 20;270(3):1230-7
pubmed: 7836384
Breast Cancer Res Treat. 2012 Nov;136(1):67-75
pubmed: 22976806
Int J Radiat Biol. 2021;97(5):593-631
pubmed: 33703994
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34389617
Sci Rep. 2020 May 20;10(1):8388
pubmed: 32433492
Cancer Biol Med. 2020 Feb 15;17(1):44-59
pubmed: 32296576
Ann Oncol. 2020 May;31(5):569-581
pubmed: 32278621
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
Sci Rep. 2021 Feb 17;11(1):3986
pubmed: 33597614
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
J Natl Compr Canc Netw. 2020 Apr;18(4):479-489
pubmed: 32259782
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61
pubmed: 27251642
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
NPJ Breast Cancer. 2019 Oct 29;5:37
pubmed: 31700993
Cancer Metab. 2017 Aug 22;5:6
pubmed: 28852500
PLoS One. 2011;6(12):e28403
pubmed: 22220191
Cancer Immunol Immunother. 2014 May;63(5):449-58
pubmed: 24609989
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Exp Ther Med. 2021 Jun;21(6):584
pubmed: 33850556
Int J Cancer. 2011 May 1;128(9):2085-95
pubmed: 20607826
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Clin Cancer Res. 2015 Dec 15;21(24):5460-8
pubmed: 26130460
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
J Clin Oncol. 2010 Oct 1;28(28):4316-23
pubmed: 20805453
J Appl Physiol (1985). 2000 Apr;88(4):1474-80
pubmed: 10749844
Cancer J. 2021 Jan-Feb 01;27(1):59-66
pubmed: 33475294
Transl Oncol. 2011 Dec;4(6):321-7
pubmed: 22190995
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Curr Top Med Chem. 2018;18(6):494-504
pubmed: 29788892
Sci Signal. 2021 Jul 20;14(692):
pubmed: 34285132
J Biol Chem. 2009 Jun 19;284(25):16767-16775
pubmed: 19386601
Breast Cancer Res Treat. 2012 Dec;136(3):795-804
pubmed: 23124476
Ann Oncol. 2020 Sep;31(9):1216-1222
pubmed: 32461104
Am Soc Clin Oncol Educ Book. 2016;35:34-42
pubmed: 27249684
Cell Metab. 2006 Mar;3(3):187-97
pubmed: 16517406
Clin Cancer Res. 2021 Jun 1;27(11):3061-3068
pubmed: 33727258
J Biol Chem. 2002 Jun 28;277(26):23111-5
pubmed: 11943784
Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):103-11
pubmed: 8641905
Cell. 2017 May 4;169(4):570-586
pubmed: 28475890
Pathobiology. 2013;80(1):41-52
pubmed: 22832328
J Pathol. 2005 Jul;206(3):291-304
pubmed: 15906272
Clin Cancer Res. 2013 Sep 15;19(18):5158-69
pubmed: 23833310
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
J Natl Cancer Inst. 2020 Jul 1;112(7):708-719
pubmed: 31665482
Hum Pathol. 2016 Jan;47(1):52-63
pubmed: 26527522
Breast Cancer Res. 2011;13(6):R126
pubmed: 22151962
Cell Rep. 2019 Oct 1;29(1):135-150.e9
pubmed: 31577944
J Immunol. 2011 Mar 15;186(6):3299-303
pubmed: 21317389
Cancer Imaging. 2021 Sep 27;21(1):55
pubmed: 34579791
Cancer Res. 2016 Jul 15;76(14):4136-48
pubmed: 27206847
Future Oncol. 2009 Jun;5(5):581-5
pubmed: 19519197
Lancet Oncol. 2021 Apr;22(4):499-511
pubmed: 33676601
Curr Opin Oncol. 2012 Nov;24(6):650-4
pubmed: 22913968
Cancer. 2008 Mar 1;112(5):995-1000
pubmed: 18098228
Diagn Interv Radiol. 2018 Nov;24(6):336-341
pubmed: 30406761
PLoS One. 2018 Sep 24;13(9):e0203965
pubmed: 30248111
Clin Cancer Res. 2017 Apr 15;23(8):1981-1987
pubmed: 27698001
Nat Immunol. 2020 Mar;21(3):298-308
pubmed: 32066953
Int J Radiat Oncol Biol Phys. 1985 May;11(5):943-50
pubmed: 3988563
Mol Ther Nucleic Acids. 2016 Aug 30;5(8):e357
pubmed: 27574783
Ann Oncol. 2019 Aug 1;30(8):1279-1288
pubmed: 31095287
Cancer Cell. 2022 Feb 14;40(2):201-218.e9
pubmed: 35090594
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Ann Oncol. 2021 Aug;32(8):994-1004
pubmed: 34219000
Ann Oncol. 2021 Oct;32(10):1236-1244
pubmed: 34311075
Medicine (Baltimore). 2017 Nov;96(45):e8557
pubmed: 29137072
Indian J Med Res. 2008 Aug;128(2):140-8
pubmed: 19001677
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075
pubmed: 29532102
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Cancers (Basel). 2019 Jul 17;11(7):
pubmed: 31319613
Clin Cancer Res. 2011 Oct 1;17(19):6250-6261
pubmed: 21844011
Dis Markers. 2017;2017:7687851
pubmed: 29434411
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
Clin Cancer Res. 2006 Sep 15;12(18):5260-4
pubmed: 17000656
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Med (N Y). 2021 Jun 11;2(6):736-754
pubmed: 34223403
Oncol Rep. 2020 Sep;44(3):819-837
pubmed: 32582991
Ann Oncol. 2019 Feb 1;30(2):236-242
pubmed: 30590484
Int J Radiat Biol. 2019 Jul;95(7):912-919
pubmed: 30822194
NPJ Breast Cancer. 2022 Jan 11;8(1):3
pubmed: 35017545
EMBO Rep. 2019 Jan;20(1):
pubmed: 30429208
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
Genes Dev. 1997 Jan 1;11(1):72-82
pubmed: 9000051